{"id":7654,"date":"2005-01-29T15:25:49","date_gmt":"2005-01-29T14:25:49","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7654"},"modified":"2014-05-22T15:22:57","modified_gmt":"2014-05-22T15:22:57","slug":"long-term-response-to-ftc-in-children-is-similar-to-adults","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7654","title":{"rendered":"Long-term response to FTC in children is similar to adults"},"content":{"rendered":"<p><strong>Paul E Sax, MD, The Body<\/strong><\/p>\n<p><strong>Gilead Study FTC-203 is an ongoing, open-label study designed to evaluate the antiviral activity of FTC (emtricitabine, Emtriva) in combination with other antiretroviral drugs in pediatric patients.<\/strong><\/p>\n<p>Study subjects received FTC at a dose of 6 mg\/kg\/day up to a maximum dose of 200 mg a day; either an alcohol-free oral solution or capsules were used. If treatment naive, the patient also received stavudine (d4T, Zerit) and lopinavir\/ritonavir (LPV\/r, Kaletra); if treatment experienced and receiving lamivudine (3TC, Epivir), the patient was given emtricitabine in addition to his or her other antiretrovirals.<\/p>\n<p>A total of 71 naive and 45 experienced patients were enrolled. The mean age was 6 years old; the median HIV RNA was 4.5 log with a CD4+ cell count of 826. Fifty-three percent of the study participants were female and 69% were black. The proportion of patients achieving viral suppression at week 96 was as follows:<\/p>\n<p><strong>% patients achieving VL below 50 or 400 copies at 96 weeks<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<th>VL<\/th>\n<th>Naive pts<\/th>\n<th>Experienced pts<\/th>\n<\/tr>\n<tr>\n<td>&lt;400<\/td>\n<td>76%<\/td>\n<td>69%<\/td>\n<\/tr>\n<tr>\n<td>&lt;50<\/td>\n<td>65%<\/td>\n<td>55%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The only mutation to emerge among treatment-naive study subjects was M184V, the signature mutation of FTC. No data on tolerability was presented.<\/p>\n<p>The results of this study suggest that FTC in pediatric patients achieves comparable antiviral activity to FTC in adults. As noted in adult studies of lopinavir\/ritonavir with 3TC or FTC plus a third nucleoside\/nucleotide reverse transcriptase inhibitor, the most likely mutation to emerge with treatment failure is M184V.<\/p>\n<h3>Comment<\/h3>\n<p><strong>The preliminary data for FTC in children appears to be encouraging.<\/strong><\/p>\n<p><strong>This study will hopefully hasten licensing and accessibility to FTC for children, which will provide an additional option for once daily combinations.<\/strong><\/p>\n<p><strong>FTC liquid formulation is currently available in the UK on a named patient basis by contacting Rachel Hutchings at the medical department at Gilead Sciences on 01223 897345.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>Harris J et al. Long-term virologic response and genotypic findings in HIV-1 infected pediatric patients receiving emtricitabine (FTC) once daily (QD). 41st ICAAC, Washington, 2004. Poster H-855.<\/p>\n<p>Source: <a href=\"http:\/\/www.thebody.com\">thebody.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paul E Sax, MD, The Body Gilead Study FTC-203 is an ongoing, open-label study designed to evaluate the antiviral activity of FTC (emtricitabine, Emtriva) in combination with other antiretroviral drugs in pediatric patients. Study subjects received FTC at a dose &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,32],"tags":[99],"class_list":["post-7654","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-paediatric-care","tag-icaac-44th-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7654"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7654\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}